Comparative Pharmacology
Head-to-head clinical analysis: ACULAR LS versus ACUVAIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACULAR LS versus ACUVAIL.
ACULAR LS vs ACUVAIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
1 drop in the affected eye(s) four times daily
1 drop in the affected eye 4 times daily.
None Documented
None Documented
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
Category C
Category C
NSAID Ophthalmic
NSAID Ophthalmic